Nutriband Reports 50.87% Revenue Growth, $6.9M Cash; Advances AVERSA Fentanyl Toward NDA With No Phase 2/3 Trials Required
Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) reported its financial results for the six months ended July 31, 2025. The company reported a strong cash position at quarter end, reinforcing its ability to advance the
